open access

Vol 83, No 2 (2015)
ORIGINAL PAPERS
Submitted: 2015-03-10
Accepted: 2015-03-10
Get Citation

Interferon gamma release assays based on M. tuberculosis- -specific antigens in sarcoidosis patients

Anna Kempisty, Beata Białas -Chromiec, Dagmara Borkowska, Jan Kuś
DOI: 10.5603/PiAP.2015.0020
·
Pneumonol Alergol Pol 2015;83(2):126-134.

open access

Vol 83, No 2 (2015)
ORIGINAL PAPERS
Submitted: 2015-03-10
Accepted: 2015-03-10

Abstract

Introduction: This study is a part of the project on interferon gamma release assays performed in the group of untreated sarcoidosis patients formerly BCG vaccinated. The aim of the study was to assess the rate of positive commercial interferon g release assays in sarcoidosis patients. We discussed the results in the context of hypothesis that M. tuberculosis antigens may play a role in the pathogenesis of sarcoidosis.

Material and methods: 151 patients, mean age 38 ± 10.3, treatment naive, with newly diagnosed pulmonary sarcoidosis were enrolled into the study. All participants underwent QFT-GIT assay. A subgroup of 81 patients underwent also T-SPOT.TB assay.

Results: QFT-GIT was positive in 7/151. T-SPOT.TB was positive in 3/81. There were no indeterminate results in both IGRAs. There was no statistically significant relationship between IGRAs results and sarcoidosis parameters such as the radiologic stage, disease duration and the presence of Löfgren’s syndrome.

Conclusions: In sarcoidosis patients formerly BCG vaccinated, positive rate of IGRAs was 4.6% for QFT-GIT and 3.7% for T-SPOT. TB. We did not find the influence of the selected parameters of sarcoidosis on IGRAs results.

Abstract

Introduction: This study is a part of the project on interferon gamma release assays performed in the group of untreated sarcoidosis patients formerly BCG vaccinated. The aim of the study was to assess the rate of positive commercial interferon g release assays in sarcoidosis patients. We discussed the results in the context of hypothesis that M. tuberculosis antigens may play a role in the pathogenesis of sarcoidosis.

Material and methods: 151 patients, mean age 38 ± 10.3, treatment naive, with newly diagnosed pulmonary sarcoidosis were enrolled into the study. All participants underwent QFT-GIT assay. A subgroup of 81 patients underwent also T-SPOT.TB assay.

Results: QFT-GIT was positive in 7/151. T-SPOT.TB was positive in 3/81. There were no indeterminate results in both IGRAs. There was no statistically significant relationship between IGRAs results and sarcoidosis parameters such as the radiologic stage, disease duration and the presence of Löfgren’s syndrome.

Conclusions: In sarcoidosis patients formerly BCG vaccinated, positive rate of IGRAs was 4.6% for QFT-GIT and 3.7% for T-SPOT. TB. We did not find the influence of the selected parameters of sarcoidosis on IGRAs results.

Get Citation

Keywords

sarcoidosis, interferon gamma release assays, latent tuberculosis infection

About this article
Title

Interferon gamma release assays based on M. tuberculosis- -specific antigens in sarcoidosis patients

Journal

Advances in Respiratory Medicine

Issue

Vol 83, No 2 (2015)

Pages

126-134

DOI

10.5603/PiAP.2015.0020

Bibliographic record

Pneumonol Alergol Pol 2015;83(2):126-134.

Keywords

sarcoidosis
interferon gamma release assays
latent tuberculosis infection

Authors

Anna Kempisty
Beata Białas -Chromiec
Dagmara Borkowska
Jan Kuś

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl